Entwicklung und Pilottestung der deutschen Version des Chemical
Coping Index an einer somatoformen Patientenstichprobe: selbstmedikativer
Medikamentengebrauch zur Bewältigung psychosozialer
Belastung
Subtitle: Development and pilot testing of the German version of the
Chemical Coping Index for patients with somatoform disorders: medication misuse
as coping with Distress
Affiliations: Institut für Medizinische Psychologie,
Universitätsklinikum Hamburg-Eppendorf | Psychosomatische Medizin und Psychotherapie,
Schön Klinik Hamburg-Eilbek | Institut für Psychosomatische Medizin und
Psychotherapie, Universitätsklinikum Hamburg-Eppendorf
Note: [] Korrespondenzadresse: Dipl.-Psych. Leon Philip Sautier, Institut
und Poliklinik für Medizinische Psychologie, Zentrum für
Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf,
Martinistraße 52 – W26, Hamburg. Tel.: (040) 7410 – 54392; Fax: (040) 7410
– 54940; Email: [email protected]
Abstract: Objectives: The concept of Chemical Coping proposes that patients
suffering from chronic pain might utilize their pain medication to ameliorate
coexisting distressful emotional states. Primary objective of this study was
the preliminary evaluation of the German version of the Chemical Coping Index
(CCI-D) in 80 patients with somatoform diseases as well as the development and
evaluation of a short-scale. Methods: The psychometric properties of the CCI-D were tested via
item analysis and reliability analysis (Cronbach's coefficient alpha). To
evaluate the short-scale of the CCI-D item analysis, reliability analysis,
confirmatory factor analysis and concurrent correlation analysis were performed. Results: The scale structure of the original version of the CCI
could not be replicated distinctly. The CCI-D12 was highly reliable (α =
0.92), explained 51% of variance and showed plausible values in confirmatory
modell-fit-indices. Chemical Coping was significantly correlated with an
increased intake of pain medication (P ⩽ 0.01), defiance of medical intake
instructions (P ⩽ 0.01), and highly associated with experienced withdrawal
symptoms (P ⩽ 0.001), fear (P ⩽ 0.05), hypochondria (P ⩽ 0.01),
psychosocial distress (P ⩽ 0.001), and alexithymia (P ⩽ 0.001).
Patients did not differ significantly in somatization and pain disability. Conclusion: The German short-scale CCI-D12 is a reliable and valid
instrument assessing patterns of chemical coping and misuse of pain
medication.
Keywords: Chemical coping, drug abuse, somatoform disorders, coping with pain
